Impact on Health-Related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: Results from a Randomized Controlled Trial.
Cancer
Malnutrition
Palliative care
Parenteral nutrition
Zelen's method
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
09
11
2019
accepted:
07
02
2020
pubmed:
27
3
2020
medline:
22
6
2021
entrez:
27
3
2020
Statut:
ppublish
Résumé
Malnutrition worsens health-related quality of life (HRQoL) and the prognosis of patients with advanced cancer. This study aimed to assess the clinical benefits of parenteral nutrition (PN) over oral feeding (OF) for patients with advanced cancer cachexia and without intestinal impairment. In this prospective multicentric randomized controlled study, patients with advanced cancer and malnutrition were randomly assigned to optimized nutritional care with or without supplemental PN. Zelen's method was used for randomization to facilitate inclusions. Nutritional and performance status and HRQoL using the European Organization for Research and Treatment of Cancer QLQ-C15-PAL questionnaire were evaluated at baseline and monthly until death. Primary endpoint was HRQoL deterioration-free survival (DFS) defined as a definitive deterioration of ≥10 points compared with baseline, or death. Among the 148 randomized patients, 48 patients were in the experimental arm with PN, 63 patients were in the control arm with OF only, and 37 patients were not included because of early withdrawal or refused consent. In an intent to treat analysis, there was no difference in HRQoL DFS between the PN arm or OF arm for the three targeted dimensions: global health (hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.88-1.94; p = .18), physical functioning (HR, 1.58; 95% CI, 1.06-2.35; p = .024), and fatigue (HR, 1.19; 95% CI, 0.80-1.77; p = .40); there was a negative trend for overall survival among patients in the PN arm. In as treated analysis, serious adverse events (mainly infectious) were more frequent in the PN arm than in the OF arm (p = .01). PN improved neither HRQoL nor survival and induced more serious adverse events than OF among patients with advanced cancer and malnutrition. Clinical trial identification number. NCT02151214 IMPLICATIONS FOR PRACTICE: This clinical trial showed that parenteral nutrition improved neither quality of life nor survival and generated more serious adverse events than oral feeding only among patients with advanced cancer cachexia and no intestinal impairment. Parenteral nutrition should not be prescribed for patients with advanced cancer, cachexia, and no intestinal failure when life expectancy is shorter than 3 months. Further studies are needed to assess the useful period with a potential benefit of artificial nutrition for patients with advanced cancer.
Sections du résumé
BACKGROUND
Malnutrition worsens health-related quality of life (HRQoL) and the prognosis of patients with advanced cancer. This study aimed to assess the clinical benefits of parenteral nutrition (PN) over oral feeding (OF) for patients with advanced cancer cachexia and without intestinal impairment.
MATERIAL AND METHODS
In this prospective multicentric randomized controlled study, patients with advanced cancer and malnutrition were randomly assigned to optimized nutritional care with or without supplemental PN. Zelen's method was used for randomization to facilitate inclusions. Nutritional and performance status and HRQoL using the European Organization for Research and Treatment of Cancer QLQ-C15-PAL questionnaire were evaluated at baseline and monthly until death. Primary endpoint was HRQoL deterioration-free survival (DFS) defined as a definitive deterioration of ≥10 points compared with baseline, or death.
RESULTS
Among the 148 randomized patients, 48 patients were in the experimental arm with PN, 63 patients were in the control arm with OF only, and 37 patients were not included because of early withdrawal or refused consent. In an intent to treat analysis, there was no difference in HRQoL DFS between the PN arm or OF arm for the three targeted dimensions: global health (hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.88-1.94; p = .18), physical functioning (HR, 1.58; 95% CI, 1.06-2.35; p = .024), and fatigue (HR, 1.19; 95% CI, 0.80-1.77; p = .40); there was a negative trend for overall survival among patients in the PN arm. In as treated analysis, serious adverse events (mainly infectious) were more frequent in the PN arm than in the OF arm (p = .01).
CONCLUSION
PN improved neither HRQoL nor survival and induced more serious adverse events than OF among patients with advanced cancer and malnutrition. Clinical trial identification number. NCT02151214 IMPLICATIONS FOR PRACTICE: This clinical trial showed that parenteral nutrition improved neither quality of life nor survival and generated more serious adverse events than oral feeding only among patients with advanced cancer cachexia and no intestinal impairment. Parenteral nutrition should not be prescribed for patients with advanced cancer, cachexia, and no intestinal failure when life expectancy is shorter than 3 months. Further studies are needed to assess the useful period with a potential benefit of artificial nutrition for patients with advanced cancer.
Identifiants
pubmed: 32212354
doi: 10.1634/theoncologist.2019-0856
pmc: PMC7216468
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e843-e851Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Références
Clin Transl Oncol. 2018 Sep;20(9):1202-1211
pubmed: 29500682
Nutrition. 1990 May-Jun;6(3):233-40
pubmed: 2152097
Gynecol Oncol. 2006 Oct;103(1):176-80
pubmed: 16564074
JPEN J Parenter Enteral Nutr. 2018 Jul;42(5):933-941
pubmed: 30001463
Contemp Clin Trials. 2006 Aug;27(4):305-19
pubmed: 16455306
Clin Nutr. 2015 Oct;34(5):825-37
pubmed: 25288565
Ann Oncol. 2018 Feb 1;29(suppl_2):ii27-ii34
pubmed: 29741571
Ann Palliat Med. 2016 Jan;5(1):42-9
pubmed: 26841814
Nat Rev Clin Oncol. 2013 Feb;10(2):90-9
pubmed: 23207794
JPEN J Parenter Enteral Nutr. 2014 Feb;38(2):196-204
pubmed: 24748626
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Oncologist. 2015 Jan;20(1):77-83
pubmed: 25480826
BMC Cancer. 2018 Oct 17;18(1):990
pubmed: 30332998
Oncologist. 2019 Sep;24(9):e960-e967
pubmed: 30975922
Oncologist. 2018 May;23(5):580-585
pubmed: 29222198
Nutr J. 2012 Apr 24;11:27
pubmed: 22531478
Ann Oncol. 2014 Feb;25(2):487-93
pubmed: 24406425
Am J Clin Nutr. 2013 Oct;98(4):1012-9
pubmed: 23966429
Lancet. 1984 Jul 28;2(8396):226-7
pubmed: 6146782
Crit Rev Oncol Hematol. 2012 Oct;84(1):26-36
pubmed: 22365185
Clin Nutr. 2017 Oct;36(5):1187-1196
pubmed: 28689670
Trials. 2014 Sep 24;15:370
pubmed: 25248371
JPEN J Parenter Enteral Nutr. 2007 Nov-Dec;31(6):508-10
pubmed: 17947608
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
Oncologist. 2016 Apr;21(4):393-8
pubmed: 26984447
Nutrition. 2019 Nov - Dec;67-68:110539
pubmed: 31522087
Control Clin Trials. 1997 Dec;18(6):628-36; discussion 661-6
pubmed: 9408725
Curr Opin Clin Nutr Metab Care. 2011 May;14(3):250-4
pubmed: 21415735
Eur J Cancer. 2006 Jan;42(1):55-64
pubmed: 16162404
J Palliat Med. 2010 Jul;13(7):837-40
pubmed: 20636154
CMAJ. 2017 Apr 3;189(13):E484-E493
pubmed: 28385893
Cancer Med. 2017 Jul;6(7):1799-1806
pubmed: 28557362
Ann Palliat Med. 2016 Jan;5(1):30-41
pubmed: 26841813
N Engl J Med. 1979 May 31;300(22):1242-5
pubmed: 431682
Crit Rev Oncol Hematol. 2019 Jul;139:96-107
pubmed: 31150954
Support Care Cancer. 2019 Jun;27(6):1973-1984
pubmed: 30863893
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
Oncologist. 2018 Jan;23(1):97-104
pubmed: 28935775
Clin Nutr. 2019 Feb;38(1):182-190
pubmed: 29305245
Cancer. 2004 May 1;100(9):1967-77
pubmed: 15112279
J Natl Cancer Inst. 2012 Mar 7;104(5):371-85
pubmed: 22345712
Oncologist. 2016 Nov;21(11):1387-1395
pubmed: 27449522
BMC Cancer. 2014 Aug 15;14:593
pubmed: 25128023
Clin Nutr. 2007 Jun;26(3):289-301
pubmed: 17368656
N Engl J Med. 1985 Mar 14;312(11):665-73
pubmed: 3883167
Support Care Cancer. 2018 Aug;26(8):2793-2799
pubmed: 29508138
Qual Life Res. 2015 Jan;24(1):5-18
pubmed: 24277234
Clin Nutr. 2019 Feb;38(1):477
pubmed: 30528950